NLS Pharmaceutics AG
NLSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,589 | $897,900 | $1,015,624 | $654,835 |
| - Cash | $1,665 | $898 | $8,948 | $5,431 |
| + Debt | $0 | $1,634 | $0 | $0 |
| Enterprise Value | -$77 | $898,636 | $1,006,676 | $649,404 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$3 | -$11 | -$11 | -$10 |
| % Margin | – | – | – | – |
| EBITDA | -$3,633 | -$11,796 | -$15,471 | -$11,851 |
| % Margin | – | – | – | – |
| Net Income | -$1,981 | -$12,172 | -$16,496 | -$11,946 |
| % Margin | – | – | – | – |
| EPS Diluted | -26.3 | -3.2 | -8.4 | -8.1 |
| % Growth | -721.9% | 61.9% | -3.7% | – |
| Operating Cash Flow | -$4,268 | -$9,684 | -$13,879 | -$14,936 |
| Capital Expenditures | -$4 | -$0 | $0 | -$40 |
| Free Cash Flow | -$4,272 | -$9,684 | -$13,879 | -$14,976 |